IP Library Granted Patent US 8,101,600
Granted Patent B2
US 8,101,600 · App. 12/641,968 · Granted Jan 24, 2012

Method of treating depression

Assignee: Brookhaven Science Associates, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,101,600
App. No.
12/641,968
Granted
Jan 24, 2012
Kind
B2
Abstract

Methods for treatment of depression-related mood disorders in mammals, particularly humans are disclosed. The methods of the invention include administration of compounds capable of enhancing glutamate transporter activity in the brain of mammals suffering from depression. ATP-sensitive K + channel openers and β-lactam antibiotics are used to enhance glutamate transport and to treat depression-related mood disorders and depressive symptoms.

Claims (5)

1. A method of treating a depression-related mood disorder in a human comprising administering to the human in need thereof a therapeutically effective amount of a K ATP channel opener wherein the opener is selected from the group consisting of diazoxide and iptakalim.

2. The method of claim 1 in which the mood disorder is Major Depressive Disorder.

3. A method of increasing glutamate uptake by brain astrocytes in a human suffering from depression comprising administering to the human in need thereof a therapeutically effective amount of a K ATP channel opener wherein the opener is selected from the group consisting of diazoxide and iptakalim.

4. A method of treating a depressive symptom in a human comprising administering to the human suffering from depression a therapeutically effective amount of a K ATP channel opener wherein the opener is selected from the group consisting of diazoxide and iptakalim.

5. The method of claim 4 in which the depressive symptom is selected from the group consisting of depressed mood, loss of interest or pleasure, loss of appetite, sleep disturbance, psychomotor changes, fatigue, a sense of worthlessness, impaired concentration, and thoughts of death.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 2, 2010
From: BROOKHAVEN SCIENCE ASSOCIATES
To: ENERGY, UNITED STATES DEPARTMENT OF
Reel/Frame 024178/0444 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2009
From: HENN, FRITZ
To: BROOKHAVEN SCIENCE ASSOCIATES, LLC
Reel/Frame 023676/0711 →
Continuity (2)
Provisional Application 61140150 · Dec 23, 2008
Related Publication 20100160300A1 · Jun 24, 2010